Daniel F Wyss

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 4

Top Topics

Randomized Controlled Trial

Immune Response

Top Venues

Science progress

Science (New York, N.Y.)

Merck and Co Inc Kenilworth

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Merck and Co Inc Kenilworth

United States

BioNMR Lead/Senior Principal Scientist

Publications

Justyna Sikorska, Daniel F Wyss
Recent developments in understanding RIG-I's activation and oligomerization. Science progress 107 (3) (2024)
Justyna Sikorska, Daniel F Wyss
Recent developments in understanding RIG-I's activation and oligomerization. Science progress 107 (3) (2024)
Justyna Sikorska, Daniel F Wyss
Recent developments in understanding RIG-I's activation and oligomerization. Science progress 107 (3) (2024)
Bo-Sheng Pan, Samanthi A Perera, Jennifer A Piesvaux, Jeremy P Presland, Gottfried K Schroeder, Jared N Cumming, Benjamin Wesley Trotter, Michael D Altman, Alexei V Buevich, Brandon Cash, Saso Cemerski, Wonsuk Chang, Yiping Chen, Peter J Dandliker, Guo Feng, Andrew M Haidle, Timothy Henderson, James Jewell, Ilona Kariv, Ian Knemeyer, Johnny E Kopinja, Brian M Lacey, Jason Laskey, Charles A Lesburg, Rui Liang, Brian J Long, Min Lu, Yanhong Ma, Ellen C Minnihan, Greg O'Donnell, Ryan Otte, Laura Price, Larissa Rakhilina, Berengere Sauvagnat, Sharad K Sharma, Sriram Tyagarajan, Hyun Woo, Daniel F Wyss, Serena Xu, David Jonathan Bennett, George H Addona
An orally available non-nucleotide STING agonist with antitumor activity. Science (New York, N.Y.) 369 (6506) (2020)